Intercell Reports Study Showing Japanese Encephalitis Vaccine is Safe and Immunogenic in Children at ASTMH Meeting in New Orleans

» Presentation at ASTMH Meeting Underscores Safety and Immunogenicity
of Vaccine in a Phase II trial in children
» Additional Presentation
Demonstrates Excellent Safety during
6-Month of Follow-Up across
Phase III trials in adults
» Marketing approval for the adult
vaccine in the U.S., Europe
and Australia expected for 2008

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

research

Wien (euro adhoc) - Vienna/Austria, Cambridge and New Orleans/USA,
December 10, 2008 - Intercell AG (VSE: ICLL) today presented results
of a clinical study of its Japanese Encephalitis vaccine IC51 in
children at the American Society for Tropical Medicine and Hygiene
Annual Meeting in New Orleans. The clinical study in children from 1
to 3 years of age demonstrated excellent immunogenicity with a safety
profile similar to placebo.

The company also presented follow-up data demonstrating the safety of
IC51 in vaccines aged 18 years and older, followed for at least 6
months and for 24 months in a long-term follow-up study. In addition,
Novartis Vaccines, which will market and distribute the vaccine in
the U.S., Europe and other parts of the world, hosted a symposium at
the meeting that gave an overview of the risk of the virus in
tourists, expatriates and military personnel.

"These results convincingly demonstrate the strengths of our vaccine,
and the encouraging safety data underscores the fact that IC51 is a
major and welcome step forward in the prevention of one of Asia's
deadliest infections," said Thomas Lingelbach, Chief Operating
Officer of Intercell "We look forward to working with our partners,
Novartis and CSL, to commercialize this product in the U.S., Europe
and Australia next year."

Japanese Encephalitis, a deadly mosquito-borne infection that kills
as many as 30 percent who show symptoms, is a significant and serious
public health threat in Asia, where the disease is endemic. As many
as 50,000 are diagnosed with the disease every year.

"We are pleased with the progress of Intercell's international
licensing processes for a vaccine for such a significant unmet
medical need. We have aligned our efforts to prepare for successful
product launches for the traveler markets starting in early 2009",
said Dr. Andrin Oswald, Chief Executive Officer of Novartis Vaccines
and Diagnostics.

Study results - IC51 in children

The open-label pediatric study compared 48 children who were given
IC51 at either the standard dose or a half dose with 12 children
given a comparator Japanese Encephalitis vaccine called JenceVac®.
More than 95 percent of children who received Intercell´s vaccine
regardless of dose, generated a protective antibody response,
compared with 90.9 percent of those who received the comparator
vaccine. IC51 showed a good safety profile when given in the full and
half adult dose. All observed adverse events were mild in nature.

Study results - IC51 in adults

The 6 months safety data analysis pooled more than 4,700 volunteers,
including 3,558 volunteers who received IC51. Local reactions
affected 54.1% in the IC51 group vs. 61.1% in the JE-VAX® group, a
statistically significant difference.

About Japanese Encephalitis

Japanese Encephalitis is a mosquito-borne infection that strikes
30,000 to 50,000 a year, causing 10-15,000 deaths up to 50% of
survivors have persistent neurological sequelae. Japanese
Encephalitis is the leading cause of viral neurological disease and
disability in Asia, and is the most important viral encephalitis in
Asia. The disease is most common in several developing countries in
Asia. No treatment is currently available; only vaccination
effectively prevents the disease. Though other vaccines have been
available in the past, use of those products has been limited by
reports of neurological reactions.

About Intercell's JE vaccine IC51

Intercell's novel JE vaccine is a purified, inactivated vaccine for
active immunization against the Japanese Encephalitis virus. With
over 3 billion people living in endemic areas, Japanese Encephalitis,
a mosquito-borne flaviviral infection, is the leading cause of
childhood encephalitis and viral encephalitis in Asia. The vaccine
was developed for over 10 years under a Collaborative Research and
Development Agreement (CRADA) with the Walter Reed Army Institute of
Research (WRAIR).

Intercell's Phase III trials for the vaccine found that the vaccine
demonstrated excellent immunogenicity against Japanese Encephalitis
and an overall clinical safety profile similar to placebo combined
with an excellent local tolerability profile. That data was published
in The Lancet in December 2007:

» The immunogenicity was comparable to that of the U.S. licensed
product, JE-VAX® » Intercell's vaccine demonstrated an overall
clinical safety profile similar to placebo » Further, Intercell's
JE vaccine had an excellent local tolerability profile in the
head-to-head study with JE-VAX®

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market